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Relationship between clinicopathologic
factors and FDG avidity in radioiodinenegative recurrent or metastatic
differentiated thyroid carcinoma
Le Ngoc Ha1†, Amir Iravani2†, Nguyen Thi Nhung1, Ngo Thi Minh Hanh3, Febby Hutomo4 and Mai Hong Son1*†

Abstract
Background: In this study, we investigated the relationship between clinicopathologic factors, BRAFV600E mutation
status and [18F] F-fluoro-2-deoxyglucose (FDG) avidity in patients with radioiodine (RAI)-negative recurrent or
metastatic differentiated thyroid cancer (DTC).
Methods: From 2015 to 2018 all patients with suspected recurrent or metastatic radioiodine-negative DTC patients
who underwent FDG positron emission tomography/computed tomography (PET/CT) were retrospectively
reviewed. Suspected lesions on FDG PET/CT were biopsied and underwent BRAFV600E mutation testing by
immunohistochemistry and real-time PCR. Tumor size, recurrent versus metastatic disease, histopathologic features
including classical type versus aggressive subtypes (poorly differentiated, tall cell, columnar cell, hobnail variants)
and BRAFV600E mutation status were correlated with the SUVmax of highest hypermetabolic lesions on FDG PET/CT
by the univariate analysis using logistic regression.
Results: Sixty-three consecutive patients, 55 (87.3%) female, with median age of 48 (range 17–81) were included.
The majority of patients had BRAFV600E mutation and classical subtype, 55/63 (87.3%) and 45/63(71.4%), respectively.
Thyroglobulin at the time of suspected recurrence was 262.7 ng/ml (range 16.3–1000) and patients received a
median 3 prior RAI treatments. Fifty-four patients (85.7%) had local recurrence. The majority of patients 58/63
(92.1%) had FDG-avid disease on PET/CT. On univariate analysis, tumor size aggressive histopathologic types and
distant metastasis are the significant factors for predicting FDG uptake, p = 0.04, p = 0.001 and p = 0.004 respectively.
Although FDG uptake of BRAFV600E bearing recurrent/metastatic RAIR DTC lesions was higher than those without
the mutation, the difference did not reach statistical significance, SUVmax of 7.11 versus 4.91, respectively, p = 0.2.
Conclusion: The majority of recurrent or metastatic RAI-negative DTC have BRAFV600E mutation and detectable
disease on FDG PET/CT. FDG avidity of the recurrent or metastatic RAI-negative DTC is independently associated
with the aggressive histopathologic features.
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Key points
Question: Is there a relationship between clinicopathological features of recurrent or metastatic RAI-negative
DTC and FDG-avidity on PET/CT?
Introduction
Thyroid carcinoma is one of the most popular endocrine
cancer worldwide. Differentiated thyroid cancer (DTC)
accounts for 90% of all thyroid cancer types [1]. Approximately 5% of patients with DTC follow a more aggressive course with radioiodine (RAI)-refractory or
RAI-negative disease, often becoming the cause of mortality associated with tumor recurrences and distant metastases [2]. These DTC patients were predicted to have
poorer prognosis and limited effective treatments including surgery, radiation therapy, chemotherapy, immunotherapy and tyrosine kinase inhibitors [3]. As a result,
risk stratification and prognostic evaluation are required
to identify high-risk patients and guide the appropriate
treatment modality.
Histopathologic and biomolecular markers play an important role in the improvement of risk stratification in
DTC. Histopathologic subtype of thyroid cancer is
grouped as classical subtype (well-differentiated thyroid
carcinoma) and aggressive subtype (poorly differentiated,
tall cell, columnar cell, hobnail variants of DTC) [4] .
Classical subtype, characterized by a papillary and follicular variant, has an excellent prognosis, while patients
with aggressive histopatholologic features in the primary
tumor are considered at risk of developing RAIrefractory DTC [5]. BRAFV600E is the most common mutation observed in DTC and triggers tumorigenesis
through the mitogen-activated protein kinase (MAPK)
pathway [6]. Multiple studies have shown BRAFV600E
mutation is associated with poor clinicopathologic outcomes, larger tumor size, local recurrence and distant
metastases [7, 8].
[18F] F-fluorodeoxyglucose (FDG) positron emission
tomography/computed tomography (PET/CT) is a noninvasive diagnostic modality and beneficial for localizing
residual or recurrent disease, particularly when iodine
avidity of disease has been lost (RAI-negative) [9, 10].
The level of metabolic activity of the disease on FDG
PET/CT is independently associated with the patient
survival, hence may guide to individualize the intensity
of follow-up and treatment of these patients [11, 12]. A
limited number of studies have investigated the association between FDG-avidity of the tumors with
BRAFV600E mutation status and clinicopathological features [13–15]. While some studies suggest primary or
recurrent tumors bearing BRAFV600E mutation may have
higher FDG-avidity [16, 17], data on the correlation between other clinicopathological features and FDGavidity are rather sparse. Therefore, we aimed to
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determine the relationship between clinicopathologic
factors, BRAFV600E mutation status and FDG avidity in a
rather homogenous group of patients with recurrent or
metastatic RAI-negative DTC.

Methods
Patients

This is a retrospective review of all patients from 2015
to 2018 who had 1) prior RAI ([131I] treatment, 2) had
negative diagnostic or post-treatment iodine scan following suspected recurrent disease based on rising thyroglobulin (Tg) or ultrasound findings, 3) underwent FDG
PET/CT for detection of the site of recurrence. The suspected site of recurrence on either FDG PET or
contrast-enhanced component of PET/CT were biopsied
with BRAFV600E testing on the sample.
The present study protocol was reviewed and approved by the Institutional Review Board of Viet Nam
Ministry of Science and Technology (approval No. 02/
HĐTK-ĐTCT-KC.10.03/16–20).
Procedures

PET/CT examination was performed, using GE Discovery 710, according to the European Association of Nuclear Medicine (EANM) guidelines, version 1.0 [18]. For
patient preparation, the serum glucose level was checked
to exclude hyperglycemia. Afterward, the patients rested
in the waiting room before intravenous injection of 2.5
MBq/kg body weight (±10%) of FDG. Contrastenhanced CT with 100 ml of the contrast material with a
scan delay of 30 s and an injection rate of 3 ml/s from
the skull base to the mid-thigh was performed 60 min
after FDG injection. The parameters of the CT scan
were as follows: 120 kVp, 100 mA, the helical thickness
of 3.75 mm and 0.5 s/rotation. PET images were reconstructed using an iterative algorithm with attenuation
correction with CT.
Histopathologic type of thyroid cancer was divided
into classical type (well-differentiated thyroid carcinoma)
and aggressive histologic types (poorly differentiated, tall
cell, columnar cell, hobnail variants of DTC). BRAFV600E
mutation was analyzed by using immunohistochemistry
and real-time PCR. The immunohistochemical method
was performed using anti-BRAFV600E (VE1) antibody
(Ventana Medical System) on automated BenchMarch
Ultra (Ventana Medical System, USA). DNA for realtime PCR was extracted from formalin-fixed, paraffinembedded tissue obtained from core needle biopsy (n =
44) and percutaneous needle aspiration (n = 19) specimens. Each DNA sequence was read on an ABI-PRISM
3100 automatic sequencer (Applied Biosystems) in order
to determine the presence of the BRAF mutation. The
positive BRAFV600E mutation was decided by the
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concordance between the histopathologist and molecular
biologist in 108 hospital.
Qualitative and semiquantitative assessment

FDG PET/CT images were evaluated by two nuclear
medicine physicians (NMPs) blinded to the clinical data.
FDG-avid lesions are defined as uptake above that of
mediastinal blood pool activity by the consensus of two
NPMs. Semiquantitative analysis of highest hypermetabolic lesion, determined by maximum standardized uptake value (SUVmax) was assessed by automated
polygonal regions of interest (ROIs) drawing on
attenuation-corrected PET images using the GE workstation (version 4.7, GE Healthcare). For suspected malignant lesions on contrast-enhanced CT with no visual
FDG uptake on PET, the manual ROIs were drawn on
CT and cloned to co-registered PET images to record
the SUVmax. In cases of multiple malignant lesions, an
ROI was drawn on a lesion with the highest SUVmax on
PET.
Statistical analysis

Categorical values were compared utilizing the Chisquared test or Fisher’s exact test. Continuous variables
following normal distribution were compared with
paired t-test or repeated measure ANOVA and for variables not following a normal distribution with Wilcoxon
signed-rank test or Friedman test. To analyze the relationship between clinicopathologic variables and SUVmax, the univariate analysis was performed by logistic
regression. The significance threshold was set at P ≤
0.05. The statistical software Statistical Package for the
Social Sciences (SPSS) 20.0 (SPSS Inc., Chicago IL, USA)
and GraphPad Prism (version 8.0 Graphpad Software,
Inc., USA) have been used to analyze the data.

Results
Patients characteristics

Sixty-three consecutive patients, 55(84.8%) female, and 8
(15.2%) male, with the median age of 48 (range,17–81),
were included in the study. The patients had received
median 3 doses (range 1–9) of I-131 and the median
thyroglobulin (Tg) at the time of suspected recurrence
was 262.7 ng/ml (Table 1). The majority of the patients,
55/63 (89%), had BRAFV600E mutation. In regard to histopathologic variants, the proportion of classical DTC
was 45/63 (71.4%) and higher than those of aggressive
subtypes 18/63 (28.6%). There was no significant difference in the prevalence of BRAFV600E mutation by the
histopathologic subtype of DTC, 40/45 (88.9%) in classical subtype vs. 15/18 (83.3%) in aggressive subtype
(P = 0.6), respectively (Table 2).
FDG PET detected sites of hypermetabolic recurrence
or metastatic disease in most patients 58/63 (92.1%),
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while the remainder were diagnosed based on contrastenhanced CT component of the study. Fifty-four/63
(85.7%) patients had regional recurrent disease (thyroid
bed or cervical lymph nodes) while 9/63 (14.2%) patients
had distant metastatic. Of the latter group, almost all except one had also evidence of local recurrence too. The
location of metastatic lesions was mostly in cervical
lymph nodes (cervical lymph node alone was seen in 44/
63 [69.8%]) while the thyroid bed and distant metastases
alone were noted in 2/63 (3.2%) and 1/63 (1.6%), respectively (Table 1).
Relationship between SUVmax, histopathologic types and
BRAFV600E mutation

The median SUVmax of the BRAFV600E mutation tumors was not significantly higher than those of wild type
tumors, 9.5 vs. 6.8, P = 0.1 (Fig. 1). In contrast, the median SUVmax of the aggressive histopathologic subtype
was significantly higher than the classical subtype, 13.9
vs. 7.2, P = 0.0004 (Fig. 1). No significant difference in
FDG uptake was found between subgroups of classical
DTC with or without BRAFV600E mutation. However, we
observed a significant difference of SUVmax in aggressive subtypes with BRAFV600E mutation compared to
those with classic subtypes with BRAFV600E mutation,
15.1 vs. 6.2 vs. P = 0.0028 (Fig. 1).
To assess the partial volume effect and SUVmax, we
compared the SUVmax between tumors > 10 mm, < 10
mm. SUVmax of lesions > 10 mm was significantly
higher than those of lesions < 10 mm, 13.4 vs. 6.3, P =
0.0003 (Fig. 2). Consistent results were seen in the subgroup of BRAFV600E positive, between tumors larger
than 10 mm and smaller than 10 mm, 14.3 vs. 6.5, P =
0.0002 (Fig. 2).
The relationship between clinicopathologic factors and
SUVmax is detailed in Table 3. In univariate analysis,
FDG uptake was predicted by lesion size, histopathologic
type, and distant metastases, p = 0.04, p = 0.001 and p =
0.004 respectively. There was no relationship between
SUVmax and BRAFV600E mutation or Tg level on univariate analysis (Figs. 3 and 4).

Discussions
In this study, we have shown the independent association between FDG avidity and aggressive histopathologic subtypes in patients with recurrent or metastatic
RAI-negative disease. The strength of this study was that
all patients had histopathologic confirmation of recurrence or metastases and underwent BRAF mutation testing by immunohistochemically and real-time PCR
method. In the majority (92%) of the patients, FDG PET
detected sites of recurrent disease in RAI-negative patients. This was consistent with the study performed by
Rivera et al. which showed that 77% of FDG-avid
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Table 1 Clinicopathologic features of radioiodine-negative DTC patients
Clinicopathologic features

Number
(n = 63)

Age (median, range)

48 (17–81)

Percent(%)

≤ 45

31

49.2

> 45

32

50.8

Male

8

12.7

Female

55

87.3

< 600 mCi

59

93.7

≥ 600 mCi

4

6.3

Gender

Cumulative I-131administered activity

Number of I-131 treatment, median (range)

3 (1–9)

Serum Tg level (ng/ml), median (range)

262.7 (16.3–1000)

Location of lesion recurrence/metastases
Thyroid bed alone

2

3.2

Cervical lymph node alone

44

69.8

Distant metastasis alone

1

1.6

Thyroid bed and regional lymph node

8

12.7

Thyroid bed and distant metastasis

1

1.6

Regional lymph node and distant metastases

6

9.5

Thyroid bed, regional lymph node and distant metastases

1

1.6

Classical type

45

71.4

Aggressive type

18

28.6

Histopathologic type

BRAFV600E mutation
Positive

55

87.3

Negative

8

12.7

Characteristic of SUVmax
Mean (± SD)

9.1 (7.1)

Median (range)

6.5 (1.98–36.2)

SUVmax < 5

21

33.3

5 < SUVmax < 10

23

36.5

10 < SUVmax < 20

13

20.6

SUVmax > 20

6

9.5

Table 2 The relationship between BRAFV600E mutation and
histopathologic types of DTC
Histopathologictype

Classic type

Aggressive type

n

%

n

%

BRAFV600E

Positive

40

88.9%

15

83.3%

BRAFV600E

Negative

5

11.1%

3

16.7%

45

100%

18

100%

Total
a

: Fisher’s exact test

P
0.622a

recurrent or metastases in patients with RAI-refractory
disease are of aggressive subtype [19]. However, that
study did not describe a comprehensive definition of
RAI-refractory state and also did not assess the relationship between SUVmax and histopathologic factors. The
underlying mechanism of FDG avidity in aggressive
DTC cells is likely the upregulation of glucose
transporter-1 (GLUT1) and reduced expression of
sodium-iodide symporter (NIS) and this phenomenon
proposed that FDG PET/CT is an effective diagnostic
tool in aggressive subtypes of DTC [20, 21].

Ha et al. Cancer Imaging

(2021) 21:8

Page 5 of 8

Fig. 1 Distribution of SUVmax stratified by histopathologic types of DTC and BRAFV600E mutation status. * significant difference. ns: not significant

Table 3 Logistic regression analysis for the assessment of
association between various factors and SUVmax
Factors

P-value

n

Relative risk
(95% of CI)

Classic type

45

1.153 (1.048–1.269)

0.04*

Aggressive type

18

1.080 (0.924–1.263)

0.331

1.066 (0.983–1.157)

0.122

1.227 (1.084–1.389)

0.001*

0.95 (0.836–1.022)

0.125

0.923 (0.835–1.020)

0.116

0.872 (0.793–0.957)

0.004*

Histopathologic type

Mutation
BRAFV600E (+)
V600E

BRAF

(−)

55
8

Tg (ng/ml)
< 250

30

> 250

33

Lesion size
5–10 mm

38

> 10 mm

25

Recurrence/ metastases

Fig. 2 Distribution of SUVmax of DTC tumors stratified by tumor size
and BRAFV600E mutation status. * significant difference. ns:
not significant

*

Local recurrence

14

Without local recurrence

46

Lymph node metastases

59

Without lymph node metastases

4

Distant metastases

9

Without distant metastases

54

significant difference
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Fig. 3 Forty-year-old female with papillary thyroid cancer, aggressive histopathologic type, underwent total thyroidectomy and then received 131I
therapy with a total dose of 550 mCi. Diagnostic 131I whole-body scan after the 3rd treatment showed no abnormal uptake and the patient’s
stimulated Tg was > 1000 ng/ml. PET (panel A and D), CT (panel B) and fused PET/CT (panel D) images showed markedly FDG-avid metastatic
disease (SUVmax up to 35.55, cross-hair). Surgical resection of that lesion confirmed metastases of papillary thyroid carcinoma,
immunohistochemistry and real-time PCR showed BRAF V600E mutation

To our surprise, this study did not show the association between BRAFV600E mutation and FDG-avidity.
Previous studies have suggested that the SUVmax in
BRAFV600E mutation bearing tumors was significantly
higher than wild type variants in papillary thyroid cancer
(PTC) [22, 23]. It has also been shown that BRAF V600E
mutation is significantly associated with the expression
of GLUT-1 and glycolysis in thyroid cancer [24, 25]. The
prevalence of BRAFV600E mutation was 87.5% in this
study which is consistent with other studies in poorly
differentiated thyroid carcinoma and tall cell PTC [26–
28]. However, the lower number of patients in the nonBRAF mutation may have limited the statistical power of
our study. Furthermore, the result of The Cancer Genome Atlas project indicated that BRAFV600E PTC represents a diverse group of tumors, consisting of multiple
molecular subtypes, with variable degrees of thyroid differentiation [29]. Their results also suggested more refined reclassification of thyroid cancers into molecular
subtypes that better reflect their underlying signaling
and differentiation properties, and potentially better
informing the management of these patients. Whether
FDG-avidity can be used as an additional clinical tool to

further refine the subtypes of tumors with BRAFV600E
mutation may warrant further studies.
Expectedly, our study showed that lesion size is an independent factor of FDG positivity. FDG avidity is
strongly dependent on tumor size due to the partial volume effect [30]. Yoon et al. reported in the study of
DTC patients that SUVmax of the larger tumors (> 20
mm) was significantly higher than tumors with a smaller
size (< 10 mm) [31]. We assumed that the partial volume
effect may impact the SUVmax values of the smaller
tumor (< 10 mm). When the analysis was performed only
in tumors with larger size (> 10 mm), again no significant difference in SUVmax between BRAFV600E mutation and wild type patients was found.
The limitation of our study is the small number of patients in the group with negative BRAFV600E mutation in
comparison with the majority with positive mutation
which may have limited the statistical power of our
study to depict the significant difference in FDG uptake
between these two groups. Besides, the limited number
of patients in the subgroup with metastatic disease did
not allow us to investigate the relationship between
BRAFV600E mutation and histopathologic types in these
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Fig. 4 FDG PET/CT with contrast enhancement of a sixty-eight-year-old female with a diagnosis of papillary thyroid carcinoma, previously treated
with total thyroidectomy. The patient presented with serum thyroglobulin level of 500 ng/ml and negative post-therapy 131I whole-body scan
after 3rd treatment. The PET image (panel A and D) illustrated multifocal FDG uptake with the hottest lesion seen in the right axillary region
(SUVmax: 13.59) correlated with 11 × 20 mm lymph node on contrast-enhanced CT (panel B, crosshair) and fused PET/CT image (panel C,
crosshair). The histopathologic assessment of the lymph node confirmed thyroid carcinoma and immunohistochemistry and real-time PCR was
negative for BRAF V600E mutation

subcategories. As a result, SUVmax values could not be
compared to enhance our understanding of the behavior
of distant metastatic sites. All patients in our study were
completely RAI- negative with varying levels of FDG
avidity. However, in clinical practice, a mixed picture
could also be seen where both RAI-avid and FDGpositive diseases coexist. Whether these patients still
may benefit from RAI treatment or immediately need to
be considered for other therapeutic approaches is
unclear.

Conclusions
In patients with RAI-negative and suspected recurrence,
FDG PET/CT detects the sites of metastatic disease in
the majority of patients. This study suggests that aggressive histopathologic subtypes but not BRAFV600E mutation status are significantly associated with FDG-avidity
of the recurrent or metastatic lesions in RAI-negative
DTC.
Abbreviations
FDG [18F]: F-fluoro-2-deoxyglucose; DTC: Differentiated thyroid cancer; PET/
CT: Positron emission tomography/computed tomography; RAI : Radioiodine;

Tg : Thyroglobulin; EANM : European Association of Nuclear Medicine; NMPs
: Nuclear medicine physicians; SUVmax : Maximum standardized uptake
value; ROIs : Regions of interest; SPSS : Statistical Package for the Social
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PTC: Papillary thyroid cancer
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